The new recall includes nearly 4,500 devices. There have been 134 incidents so far, including 5 adverse events.  

It is still early for this new-look TAVR valve, but initial findings out of China include a procedural success rate of 100% and no deaths, disabling strokes or myocardial infarctions after 30 days. Read a full analysis from the team using the device. 

Researchers explored updated data from the AHA, noting that the number of CVD-related deaths increased from more than 874,000 in 2019 to more than 928,000 in 2020.

Fuster, one of the world’s most prominent cardiologists, said the award was a "great honor," especially since he was born in Barcelona. 

“There has never been a more exciting time to be a cardiothoracic surgeon,” the veteran surgeon said in a statement. 

Overwhelmed or confused by AI and machine learning technology? A new analysis in European Heart Journal hopes to provide some clarity. 

The topic was explored at length in a new scientific statement presented at the 59th Annual Meeting of the Society of Thoracic Surgeons.

Researchers examined data from nearly 2 million patients, sharing their full findings in JACC: Cardiovascular Imaging.

The newly approved SGLT2 inhibitor, bexagliflozin, is marketed under the name Brenzavvy. It is not recommended for patients with type 1 diabetes. 

Early mortality specifically related to complications during the TLR procedure was quite rare.